Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: Peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels

NMR in Biomedicine

Volumn 23, Issue 2, 2010, Pages 196-206

  Shemesh, Noam ^a   Sadan, Ofer ^a   Melamed, Eldad ^a   Offen, Daniel ^a   Cohen, Yoram ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Diffusion; Diffusion MRI; DWI; Excitotoxicity; Huntington's disease; Magnetic resonance; MRI; MRS; N acetyl aspartate recovery; Quinolinic acid

Indexed keywords

AFFECTED AREA; APPARENT DIFFUSION COEFFICIENT; CELLULAR LOSS; CONTROL LEVEL; EXCITOTOXICITY; HISTOLOGICAL ANALYSIS; HUNTINGTON'S DISEASE; IN-VIVO; N-ACETYL ASPARTATE; NEURONAL DAMAGE; NEURONAL DYSFUNCTION; RAT MODEL; STRIATUM;

ACIDS; ANIMALS; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; PYRIDINE; SURFACE DIFFUSION;

RECOVERY;

CHLORDANE; N ACETYLASPARTIC ACID; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CELL LOSS; CORPUS STRIATUM; DIFFUSION COEFFICIENT; EXCITOTOXICITY; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT;

ANIMALS; ASPARTIC ACID; BEHAVIOR, ANIMAL; BRAIN; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE MODELS, ANIMAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NERVOUS SYSTEM DISEASES; QUINOLINIC ACID; RATS; RATS, WISTAR;

ANIMALIA; RATTUS;

EID: 77149126405     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1443     Document Type: Article

References (49)

1. Stone TW. Endogenous neurotoxins from tryptophan. Toxicon 2001; 39: 61-73.
2. Schwarcz R, WhetsellWO, Mangano RM. Quinolinic acid - an endogenous metabolite that produces axon-sparing lesions in rat-brain. Science 1983; 219: 316-318.
3. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986; 321: 168-171.
4. Alexi T, Borlongan CV, Faull RLM, Williams CE, Clark RG, Gluckman PD, Hughes PE. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog. Neurobiol. 2000; 60: 409-470.
5. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW. and Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
6. von Horsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AMM, Paul M, Jones L, Lindenberg KS, Landwehrmeyer B, Bauer A, Li XJ, Riess O. Transgenic rat model of Huntington's disease. Hum. Mol. Gen. 2003; 12: 617-624.
7. Dunnett SB, Rosser AE. Stem cell transplantation for Huntington's disease. Exp. Neurol. 2007; 203: 279-292.
8. Ramaswamy S, Shannon KM, Kordower JH. Huntington's disease: Pathological mechanisms and therapeutic strategies. Cell Transplant. 2007; 16: 301-312.
9. Wright BLC, Barker RA. Established and emerging therapies for Huntington's disease. Curr. Mol. Med. 2007; 7: 579-587.
10. Choi IY, Lee SP, Guilfoyle DN, Helpern JA. In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurochem. Res. 2003; 28: 987-1001.
11. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. N-acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog. Neurobiol. 2007; 81: 89-131.
12. Dautry W, Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, Bloch G, Hantraye P. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J. Cereb. Blood Flow Meta. 2000; 20: 789-799.
13. Demougeot C, Garnier P, Mossiat C, Bertrand N, Giroud M, Beley A, Marie C. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J. Neurochem. 2001; 77: 408-415.
14. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-Nitropropionic acid. J. Neurosci. 1993; 13: 4181-4192.
15. Chyi T, Chang C. Temporal evolution of 3-nitropropionic acid-induced neurodegeneration in the rat brain by T-2-weighted, diffusionweighted, and perfusion magnetic resonance imaging. Neurosci. 1999; 92: 1035-1041.
16. Lee WT, Lee CS, Pan YL, Chang C. Temporal changes of cerebral metabolites and striatal lesions in acute 3-nitropropionic acid intoxication in the rat. Magn. Reson. Med. 2000; 44: 29-34.
17. Lee WT, Shen YZ, Chang C. Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: Evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neurosci. 2000; 95: 89-95.
18. Lee WT, Chang C. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog. Neurobiol. 2004; 72: 87-110.
19. Sauer D, Allegrini PR, Thedinga KH, Massieu L, Amacker H, Fagg GE. Evaluation of Quinolinic acid-induced excitotoxic neurodegeneration in rat striatum by quantitative magnetic-resonance-imaging in vivo. J. Neurosci. Methods 1992; 42: 69-74.
20. Guzman R, Meyer M, Lovblad KO, Ozdoba C, Schroth G, Seiler RW, Widmer HR. Striatal grafts in a rat model of Huntington's disease: Time course comparison of MRI and histology. Exp. Neurol. 1999; 156: 180-190.
21. TkáčI, Keene CD, Pfeuffer J, Low WC, Gruetter R. Metabolic changes in quinolinic acid-lesioned rat striatum detected noninvasively by in vivo H-1 NMR spectroscopy. J. Neurosci. Res. 2001; 66: 891-898.
22. Strauss I, Williamson JM, Bertram EH, Lothman EW, Fernandez EJ. Histological and H-1 magnetic resonance spectroscopic imaging analysis of quinolinic acid-induced damage to the rat striatum. Magn. Reson. Med. 1997; 37: 24-33.
23. Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, Offen D. Migration of neurotrophic factors-secreting mesenchymal stem cells towards a quinolinic acid lesion as viewed by MRI. Stem Cells 2008; 26: 2542-2551.
24. Paxinos G, Watson C. The rat brain, 4th ed. Academic Press: 1998.
25. Tkáč I, Starcuk Z, Choi IY, Gruetter R. In vivo H-1 NMR spectroscopy of rat brain at 1 ms echo time. Magn. Reson. Med. 1999; 41: 649-656.
26. Cobas JC, Sardina FJ. Nuclear magnetic resonance data processing. MestRe-C: A software package for desktop computers. Concepts Magn. Reson. Part A 2003; 19A: 80-96.
27. Carola V, D'Olimpio F, Brunamonti E, Mangia F, Renzi P. Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice. Behav. Brain Res. 2002; 134: 49-57.
28. de Almeida LP, Zala D, Aebischer P, Deglon N. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis. 2001; 8: 433-446.
29. Alberch J, Perez-Navarro E, Canals JM. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res. Bull. 2002; 57: 817-822.
30. Dunnett SB. Functional analysis of fronto-striatal reconstruction by striatal grafts. Neural transplantation in neurodegenerative disease. Current Status and New Directions 2000; 231: 21-41.
31. Krenitsky TA, Dillberger J, Zotova E, Arezzo JC, Koprich JB, Mortazavi F, Gates TA, Dunbar GL. KP544, a nerve growth factor amplifier: Pharmacokinetics, safety, and efficacy in the rat. Drug Dev. Res. 2004; 62: 60-70.
32. Ryu JK, Choi HB, McLarnon JG. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neurosci. 2006; 141: 1835-1848.
33. Song J, Lee ST, Kang W, Park JE, Chu K, Lee SE, Hwang T, Chung H, Kim M. Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions. Neurosci. Lett. 2007; 423: 58-61.
34. Norris DG. The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment. NMR Biomed. 2001; 1: 4.77-4.93.
35. Rudin M, Baumann D, Ekatodramis D, Stirnimann R, McAllister KH, Sauter A. MRI analysis of the changes in apparent water diffusion coefficient, T-2 relaxation time, and cerebral blood flow and volume in the temporal evolution of cerebral infarction following permanent middle cerebral artery occlusion in rats. Exp. Neurol. 2001; 169: 56-63.
36. Wick M, Nagatomo Y, Prielmeier F, Frahm J. Alteration of intracellular metabolite diffusion in rat-brain in-vivo during ischemia and reperfusion. Stroke 1995; 26: 1930-1933.
37. Duan WM, Widner H, Cameron RM, Brundin P. Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. Euro. J. of Neurosci. 1998; 10: 2595-2606.
38. Guillemin GJ, Croitoru-Lamoury J, Dormont D, Armati PJ, Brew BJ. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 2003; 41: 371-381.
39. Hoehn M, Nicolay K, Franke C, van der Sanden B. Application of magnetic resonance to animal models of cerebral ischemia. J. Magn. Reson. Imaging 2001; 14: 491-509.
40. Sotak CH. Nuclear magnetic resonance (NMR) measurement of the apparent diffusion coefficient (ADC) of tissue water and its relationship to cell volume changes in pathological states. Neurochem. Int. 2004; 45: 569-582.
41. Moseley ME, Cohen Y, Mintorovitch J, Chileuitt L, Shimizu H, Kucharczyk J, Wendland MF, Weinstein PR. Early detection of regional cerebral-ischemia in cats-comparison of diffusion-weighted and T2-weighted MRI and spectroscopy. Magn. Reson. Med. 1990; 14: 330-346.
42. Ebisu T, Rooney WD, Graham SH, Weiner MW, Maudsley AA. N-Acetylaspartate as an in-vivo marker of neuronal viability in Kainate-induced status epilepticus - H-1 magnetic-resonance spectroscopic imaging. J. Cereb. Blood Flow Meta. 1994; 14: 373-382.
43. Higuchi T, Graham SH, Fernandez EJ, Rooney WD, Gaspary HL, Weiner MW, Maudsley AA. Effects of severe global ischemia on N-acetylaspartate and other metabolites in the rat brain. Magn. Reson. Med. 1997; 37: 851-857.
44. Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998; 9: 1757-1761.
45. Demougeot C, Bertrand N, Prigent-Tessier A, Garnier P, Mossiat C, Giroud M, Marie C, Beley A. Reversible loss of N-acetyl-aspartate in rats subjected to long-term focal cerebral ischemia. J. Cereb. Blood Flow Meta. 2003; 23: 482-489.
46. Tattersfield AS, Croon RJ, Liu YW, Kells AP, Faull RLM, Connor B. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease. Neurosci. 2004; 127: 319-332.
47. Scattoni ML, Valanzano A, Popoli P, Pezzola A, Reggio R, Calamandrei G. Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease. Behav. Brain Res. 2004; 152: 375-383.
48. Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog Neuro-Psychopharmacology & Biological Psychiatry 1998; 22: 1217-1240.
49. Vinade ER, Schmidt AP, Frizzo MES, Portela LV, Soares FA, Schwalm FD, Elisabetsky E, Izquierdo I, Souza DO. Effects of chronic administered guanosine on behavioral parameters and brain glutamate uptake in rats. J. Neurosci. Res. 2005; 79: 248-253.